![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration aims to support Navega's NT-Z001, which is being evaluated in the IND enabling stage for the treatment of chronic pain associated with rare diseases such as small fiber neuropathy and primary erythromelalgia.
Lead Product(s): NT-Z001
Therapeutic Area: Neurology Product Name: NT-Z001
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Recipient: Charles River Laboratories, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2024